Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1073/pnas.1614315114 http://scihub22266oqcxt.onion/10.1073/pnas.1614315114 C5278465!5278465!28069963     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Proc+Natl+Acad+Sci+U+S+A 2017 ; 114 (4): 740-5 Nephropedia Template TP {{tp|p=28069963|t=2017. Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors |pdf=|usr=}}{{28069963}} gab.com Text Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors JO: Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=28069963 #FOAvip Immunosuppressive tumor microenvironment, insufficient migration, and reduced effector function of tumor-specific T cells are the main hurdles that hamper the efficacy of immunotherapy in treating solid tumors. In this study, we combined the strength of adoptive cell transfer (ACT) and pathogen-based cancer vaccine and developed an innovative strategy, Reenergized ACT (ReACT), to treat solid tumors. ReACT uses a pathogen not only to break the immunosuppression, but also to drive the expansion and migration of tumor-specific T cells to the site of the tumor. With this combinatorial approach, we have demonstrated that ReACT enhances antitumor efficacy in comparison with either ACT or pathogen-based cancer vaccine alone in primary tumor eradication and offers long-term protection against reoccurrence in preclinical cancer models. Twit Text FOAVip Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors ????Proc Natl Acad Sci U S A http://www.kidney.de/pget.php?&tw=1&pmid=28069963 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28069963 #FOAvip English Wikipedia <ref>{{Cite pmid|28069963}}</ref> Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors #MMPMID28069963 Xin G; Schauder DM; Jing W; Jiang A; Joshi NS; Johnson B; Cui W Proc Natl Acad Sci U S A 2017[Jan]; 114 (4): 740-5 PMID28069963show ga Immunosuppressive tumor microenvironment, insufficient migration, and reduced effector function of tumor-specific T cells are the main hurdles that hamper the efficacy of immunotherapy in treating solid tumors. In this study, we combined the strength of adoptive cell transfer (ACT) and pathogen-based cancer vaccine and developed an innovative strategy, Reenergized ACT (ReACT), to treat solid tumors. ReACT uses a pathogen not only to break the immunosuppression, but also to drive the expansion and migration of tumor-specific T cells to the site of the tumor. With this combinatorial approach, we have demonstrated that ReACT enhances antitumor efficacy in comparison with either ACT or pathogen-based cancer vaccine alone in primary tumor eradication and offers long-term protection against reoccurrence in preclinical cancer models. äPathogen boosted adoptive cell transfer immunotherapy to treat solid t(epmc).pdf DeepDyve Pubget Overpricing